On a mission to save Teva from crippling debt, Schultz stands by cost-cutting measures, scrutinizes per product profitability
SAN FRANCISCO — Kåre Schultz didn’t mince words at Teva’s JPM presentation this morning, launching his talk by outlining the company’s colossal challenges in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.